INOVIO
Manufacturing · Pennsylvania, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
660 W Germantown Pike Ste 110, Plymouth ...Phone Number
(267) 440-4200Website
www.inovio.comRevenue
-Stock Symbol
INOIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About INOVIO
Inovio Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune systems tolerance of cancerous cells; and SynCon product design is also intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. It has completed, current or planned clinical programs of its proprietary SynCon immunotherapies for HPV-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus, hepatitis B virus, HIV, Ebola, Middle East Respiratory Syndrome, and Zika virus. The companys partners and collaborators include MedImmune, LLC, the Wistar Institute, University of Pennsylvania, Defense Advanced Research Projects Agency, GeneOne Life Science, Plumbline LifeRead more
INOVIO Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is INOVIO your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when INOVIO launches new products
Click to see if INOVIO had a recent Job posting/layoffs
Check if INOVIO has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once INOVIO has new funding data
Earning: See what the market has to say on INOVIO recently announced quarterly report
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at INOVIO
INOVIO, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if INOVIO is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to INOVIO
Compare insights from companies similar to INOVIO, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$123.9M
51-200
Public
$547.1M
1994
JB
Jennifer BuellPresident and CEO of MiNK Therapeutics, Chairman, Executive Council At Agenus
Company Profile Activity
Activity Insights
INOVIO is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
INOVIO is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about INOVIO.
INOVIO financials insights
Gather financial insights about INOVIO, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2013
Stock Offering
$14M
Grant
$3.5M
2014
Stock Offering
$59.2M
2015
Stock Offering
$82.1M
Grant
$24M
2017
Stock Offering
$70.2M
2018
Grant
$56M
2019
Multiple Rounds
$98.9M
2020
Grant
$5M
INOVIO Tech Stack
A closer look at the technologies used by INOVIO
See more technologies
Most Recent Scoops
Person-Based
Pharmaceuticals
Person-Based
IPO, Finance
Project
INOVIO has been granted orphan drug designation and breakthrough therapy designation in the US for INO-3107, and has also received orphan drug designation within the EU.
Pharmaceuticals
Project
INOVIO has announced a new clinical trial for INO-5401, its glioblastoma candidate, to be sponsored by Dana-Farber Cancer Institute, which will combine INO-5401 with a dual checkpoint inhibitor from AbbVie to evaluate extension of median overall survival, with the trial planned to begin following the PDUFA date for INO-3107.
Pharmaceuticals, Clinical Operations
Project
Partnership, Medical Research, Pharmaceuticals
INOVIO News & Media
INOVIO to Report Second Quarter Financial Results on August 12, 2026
PLYMOUTH MEETING, Pa., Aug. 4, 2026 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that its second quarter...INOVIO Announces Pricing of $20.0 Million Public Offering
PLYMOUTH MEETING, Pa., July 29, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the...INOVIO Announces Proposed Public Offering
PLYMOUTH MEETING, Pa., July 29, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced...INOVIO to Participate in Upcoming Scientific and Investor Conferences
PLYMOUTH MEETING, Pa., May 28, 2026 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer and infectious diseases, today announced that it will participate in...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding INOVIO
Sign Up For FreeTo access detailed company insights
Inovio Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune systems tolerance of cancerous cells; an... Read More
